Delta T

Delta T Therapeutics is a Singapore-based biotechnology company dedicated to developing first-in-class small molecule therapeutics for cancer. The company focuses on targeting the p53 pathway, specifically addressing mutant forms of the p53 protein which are found in approximately half of all human cancers and have historically been considered "undruggable." By leveraging proprietary structural biology insights and medicinal chemistry, Delta T Therapeutics aims to restore wild-type p53 function or selectively eliminate cells harboring p53 mutations. As a spin-off from the National Cancer Centre Singapore (NCCS), the company combines deep academic research with venture backing to advance its oncology pipeline toward clinical trials.